Replies to post #364304 on Elite Pharmaceuticals Inc (ELTP)

[The ELTP King]

What news?

Nasrat REFUSED to issue a press release.

Even with news of the partnership with Dexcel that has global growth opportunities, the p/s remains suppressed. So much for good news and a rational market.

WTF!!!!!!!!!????????

Which is it?

Q1 2022 call: Our goal is to pass and/or file 4 ANDAs before December 2022. You can do the math and determine how many ANDAs we must be working on or have worked on to get 4 viable ANDAs in 2022.

Q2 2022 call: And the last one (question) is Elite still on track for filing four ANDAs in 2022? The answer is yes, we are doing well and on target.

The big question for Nasrat to answer on the next CC is - "Do you believe Elite is still on track to FILE four new ANDAs this calendar year?"